OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🟢 Outlook Therapeutics is trading 5.3% up in pre-market with no new company-specific announcement identified
Outlook Therapeutics is trading 5.33% up now at $0.67 in pre-market, though no new company-specific announcement was identified for August 26, 2026. - Latest...
🟢 Outlook Therapeutics is trading 10% up today amid stronger biotech sentiment
Outlook Therapeutics is trading 10.36% up now at $0.67, primarily supported by stronger biotechnology sentiment, with XBI up 2.06% during regular trading...
🟢 Outlook Therapeutics is trading 5% up today as Nasdaq rises 0.69%
Outlook Therapeutics is trading at $0.64, up 5.09%, as the Nasdaq rises 0.69%, providing a favorable backdrop for risk-sensitive biotechnology shares. - No...
🔴 Outlook Therapeutics is trading 5% down today as Nasdaq and S&P 500 decline
Outlook Therapeutics is trading 5.41% down at $0.61 now amid broader market weakness on August 24, 2026. - The Nasdaq Composite is down 0.78% and the S&P 500...
🔴 Outlook Therapeutics is trading 6.14% down today after discounted $55 million stock-and-warrant offering
Outlook Therapeutics is trading 6.14% down now at $0.64 as investors continue to absorb the impact of its discounted $55 million stock-and-warrant offering. -...
Outlook Therapeutics Got Its FDA Win — But Can a $9,000 Quarter and Massive Dilution Survive Until the U.S. Launch?
Shares of Outlook Therapeutics cratered to $0.68 — down 41% in a single week — after a one-two punch of dismal third-quarter results and a heavily dilutive...
🔴 Outlook Therapeutics is trading 10.1% down today after $9 thousand in third-quarter revenue
Outlook Therapeutics is trading at $0.68, down 10.1% now, after its August 14 earnings release showed only $9 thousand in third-quarter revenue. - The U.S....
🔴 Outlook Therapeutics is trading 5.5% down today after Q3 revenue fell to $9 thousand
Outlook Therapeutics is trading at $0.71, down -5.54%, after weak Q3 revenue and recent financing. • Q3 revenue was only $9 thousand, versus $1.505 million a...
🟢 Outlook Therapeutics is trading 6.11% up in pre-market after two sharply weaker sessions
Outlook Therapeutics is trading 6.11% up at $0.80 in pre-market, possibly reflecting a rebound after two sharply weaker sessions. - It closed at $0.76 on...
🟢 Outlook Therapeutics is trading 5.62% up today in after-hours trading after third-quarter earnings and launch updates
Outlook Therapeutics is trading at $0.80, +5.62% in after-hours trading following third-quarter results and LYTENAVA launch updates. - Reported third-quarter...
🔴 Outlook Therapeutics is trading 15.12% down today after discounted $55 million public offering
Outlook Therapeutics is trading 15.12% down at $0.75 after investors continued selling following its discounted $55 million public offering, priced at $0.99...
🔴 Outlook Therapeutics is trading 9.4% down today after its discounted $55 million public offering
Outlook Therapeutics is trading 9.4% down now at $0.81 after continued selling following its discounted $55 million public offering. - Financing: 55.6 million...
🔴 Outlook Therapeutics is trading 6.62% down in pre-market after pricing a discounted $55 million share-and-warrant offering
Outlook Therapeutics is trading at $0.83 (-6.62%) in pre-market after pricing a $55 million public offering of shares and warrants at $0.99, creating dilution...
Outlook Therapeutics Announces $55 Million Public Offering of Stock and Warrants
Outlook Therapeutics has entered into an underwriting agreement for a public offering of common stock and accompanying warrants, expecting to raise...
Outlook Therapeutics third quarter 2026 revenue misses estimates while company prepares for year-end LYTENAVA launch
Outlook Therapeutics reported a minimal revenue of $9 thousand for the third fiscal quarter of 2026, significantly trailing expectations as the company...
🟢 Outlook Therapeutics is trading 11.39% up in pre-market after pricing a $55 million stock-and-warrant offering
Outlook Therapeutics is trading 11.39% up at $0.99 after announcing pricing for a $55.0 million public offering of common stock and warrants. - Units are...
🔴 Outlook Therapeutics is trading 27.16% down today after pricing a discounted $55 million stock-and-warrant offering
Outlook Therapeutics is trading at $0.80 (-27.16%) after pricing 55.6 million shares with accompanying warrants at $0.99, below the $1.10 August 12 close. -...
🔴 Outlook Therapeutics is trading 14.55% down in pre-market after pricing a $55 million offering at $0.99
Outlook Therapeutics is trading 14.55% down in pre-market at $0.94 after announcing a $55.0 million underwritten public offering priced at $0.99 per...
Outlook Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
Outlook Therapeutics is projected to report consensus revenue of approximately $0.97 million and an EPS loss of $0.09, with the stock currently trading at...
Outlook Therapeutics reports $11.2M third quarter 2026 cash with runway into September
Outlook Therapeutics reported a preliminary cash balance of approximately $11.2 million for its third quarter ended June 30, 2026. Despite the July 2026 FDA...